Articles tagged with Ovarian Cancer
A new study identifies cancer-specific gene signatures for breast, lung, prostate, and ovarian cancers using surprisal analysis, a thermodynamics-based approach. This method allows researchers to understand how cellular energy is expended in cancer cells and identify potential biomarkers for early detection and therapy.
A clinical trial found that cediranib, a biological therapy, extended the time before ovarian cancer recurred and increased overall survival by up to 30% compared to chemotherapy alone. The treatment showed incremental improvements in progression-free and overall survival.
Researchers at Massachusetts General Hospital identify fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. Overexpression of the gene encoding FGF18 was associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
Researchers have identified fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. The study found that overexpression of the FGF18 gene is associated with enhanced tumor blood vessel formation and expression of cancer-promoting cytokines.
A new study found that certain immune cells help cancer stem cells survive and thrive. This finding has significant implications for the development of targeted therapies to eliminate cancer.
A Mayo Clinic study found that patients undergoing enhanced recovery pathway (ERP) for gynecologic surgery experienced decreased narcotic use, earlier discharge, and cost savings. The ERP standardized postoperative management to reduce complications and improve patient satisfaction.
A new screening strategy for ovarian cancer has shown high specificity in detecting the disease before it becomes lethal. The two-stage approach incorporates changes in a blood protein called CA125 and has been found to have a positive predictive value of 40% for invasive ovarian cancer.
A 12-year study found CA-125 to have a 99.9% specificity in detecting high-grade invasive ovarian cancers at curable stages, while the test failed to detect two borderline cases. The study's results suggest CA-125 as a promising first step in early disease detection.
Researchers identified protein biomarkers that predict ovarian cancer recurrence and chronic obstructive pulmonary disease (COPD) development. The findings suggest a potential for using protein analysis to predict patient outcomes and guide treatment decisions in both diseases.
A new biomarker, PROVAR, predicts time to ovarian cancer recurrence and distinguishes between high-risk patients. Analysis of protein biomarkers may help determine treatment plans for ovarian cancer patients.
A comprehensive compendium of mutational processes explains most mutations found in 30 common cancer types, revealing the biological processes responsible. The study identifies a family of enzymes linked to over half of cancer types, and finds that DNA damage from viruses may cause collateral genetic changes.
Researchers have direct evidence that epithelial-to-mesenchymal transition (EMT) occurs in human ovarian cancer patients, resulting in unique characteristics and resistance to chemotherapy. This finding highlights the need for combination therapy targeting both primary tumors and metastatic cells.
A new study reveals that young female cancer survivors experience significant impairment in quality of life due to fertility concerns. The study found that women's perception of their own fertility status was the most influential factor in determining overall quality of life.
Researchers developed statistical models that predict individual women's risk of each cancer based on commonly known risk factors. The models were able to accurately calculate risk ranges from 0.5% to 29.5% over the next 20 years, providing a valuable tool for clinical decision-making.
A large study of 23,000 people in Italy and Switzerland found a strong link between family history of cancer and increased risk of developing different types of cancer. The study revealed associations between specific cancers, such as oral and pharyngeal cancer, ovarian cancer, and prostate cancer, with a range of risk increases
Researchers found that ovarian cancer cells colonize milky spots in the omentum, which promotes cell growth and spread. The study suggests an alternative model of omental colonization, where both milky spots and fat cells play a role in attracting cancer cells.
Scientists have solved a key piece of the puzzle on how BRCA1 gene mutations predispose women to breast and ovarian cancers. The answer lies in the way estrogen rushes in to rescue damaged cells whose healthy functioning has been altered by oxidative stress.
A new study reveals low uptake of genetic testing for cancer-causing mutations in affected families in France. Despite steady increase in tests for BRCA1/2, MMR mutation testing remains under-used, putting whole families at risk.
African-American women with breast cancer are more likely to carry inherited genetic mutations that increase their risk for breast cancer. Genetic testing can help identify at-risk family members and provide personalized strategies for early detection and prevention.
Researchers developed a novel approach to make ovarian cancer cells susceptible to an antitumor drug, potentially improving treatment outcomes. The strategy targets telomeres and shows promise in treating other epithelial cancers.
A clinical trial led by Penn Medicine found that olaparib was effective against advanced pancreatic and prostate cancers in patients carrying BRCA 1/2 mutations. The therapy showed promise in halting disease progression, even in patients whose tumors did not shrink.
A major international study has found that sequence differences in a gene crucial to chromosome integrity predispose individuals to certain cancers. The study, published in Nature Genetics, identified variations in the TERT gene as influencing telomere length and breast and ovarian cancer risk.
The team identified 21 microRNAs associated with ovarian cancer survival and 838 target genes linked to its progression. The findings suggest a network-based approach can predict cancer survival and recurrence more accurately than individual biomarkers.
A Northwestern University study has developed a pioneering biophotonics technology to detect ovarian cancer by analyzing cells from the cervix or uterus. The partial wave spectroscopic microscopy technique shows diagnostic changes in these cells even when they appear normal under a microscope, offering a potential breakthrough in early...
A study found that ATP11B expression is correlated with higher tumor grade and cisplatin-resistance in human ovarian cancer samples. Loss of ATP11B restored sensitivity to cisplatin and reduced ovarian tumor growth in mice.
Researchers have identified the molecular mechanisms behind two rare diseases: giant axonal neuropathy and ovarian cancer. In GAN, mutations in gigaxonin disrupt neural protein degradation, leading to neurofilament accumulation. Meanwhile, ATP11B facilitates cisplatin resistance in ovarian cancer cells by mediating platinum export.
Researchers at Mount Sinai have identified a soy-based compound, genistein, that can inhibit tumor cell growth and block Wnt signaling hyperactivity in colorectal cancer. Genistein has shown promise as an adjunctive treatment for metastatic colorectal cancer when used in combination with chemotherapy.
A novel study suggests that surgical removal of an ovary and visible endometriosis significantly lower ovarian cancer risk in women with endometriosis. Hormonal treatments, however, did not show a protective effect against ovarian cancer.
Researchers developed a dual CAR approach that allows engineered T cells to selectively target tumor cells while sparing normal tissue. This innovative approach uses two separate antigen-specificity proteins, one for starting and another for boosting the immune response.
A phase I trial involving 29 patients with platinum-resistant ovarian cancer found one complete response and four partial responses to the antibody-drug conjugate DMUC5754A. The drug targets high-expression MUC16 protein in ovarian cancer cells, reducing adverse effects on healthy tissues.
A new two-step immunotherapy approach, combining dendritic cell vaccination and adoptive T-cell therapy, showed a 75% clinical benefit in 31 ovarian cancer patients. The treatment preserved tumor cells alive and used them to manufacture personalized vaccines that taught the immune system to attack the tumor.
Researchers at Mayo Clinic Cancer Center identified the HNF1B gene as a contributor to ovarian cancer susceptibility through large-scale analysis of over 16,000 women. Variations in this gene are associated with different ovarian cancer subtypes and DNA methylation patterns.
A large-scale research study has identified over 80 genetic 'spelling mistakes' linked to an increased risk of breast, prostate, and ovarian cancers. The study found that these alterations can be described as single nucleotide polymorphisms (SNPs), which are common in the DNA of patients with cancer.
Researchers have discovered five new genetic regions associated with an increased risk of ovarian cancer, found in over 40,000 women. These findings may lead to the development of new screening and prevention strategies for high-risk individuals.
Researchers at Mayo Clinic Cancer Center have identified new DNA sequences linked to an increased risk of developing breast and ovarian cancers. The findings, published in three studies, will help improve risk models and support new prevention strategies for these diseases.
Moffitt researchers have discovered four new regions of the genome linked to ovarian cancer risk, accounting for approximately 4% of inherited component. The findings are part of a coordinated series of studies involving over 250,000 individuals and provide new insights into the disease.
An international study has identified up to 80 new regions of the genome associated with increased susceptibility to breast, prostate, and ovarian cancers. Researchers have also discovered a total of 41 new genes or regions that may contribute to the development of breast cancer.
Research published in Occupational and Environmental Medicine found that night shift workers have a higher risk of developing ovarian cancer. Women who identified as 'owls' had a lower risk compared to those who were 'larks'. The study, based on data from over 1,100 women, suggests that melatonin may play a role in the increased risk.
Researchers found a population of slow-proliferating epithelial cells in the mouse ovary's hilum region that can self-renew and form tumors. These cells were previously unknown and are now believed to be the source of ovarian stem-like cells prone to cancer.
A novel stem cell niche for the ovarian surface epithelium has been identified, where ovarian carcinoma preferentially originates. This discovery provides a new guide for scientists to look for stem cell niches and sources of cancer in other transitional zones.
Women over 40 face declining fertility and require effective contraception to prevent pregnancy. Various methods are considered safe and effective, including copper IUDs, progestin implants, and sterilization, with benefits outweighing risks for most women.
Researchers found a potential therapeutic candidate, miR-506, which blocks epithelial-to-mesenchymal transition and inhibits mesenchymal markers in ovarian cancer cells. Higher miR-506 expression is associated with longer overall survival.
A phase II clinical trial shows that selumetinib, a targeted therapy, can halt growth or shrink tumors in 15% of patients with recurrent low-grade ovarian cancer. The two-year overall survival rate is 55%, and the median overall survival has not been reached due to high patient survival rates.
A two-step personalized immunotherapy treatment using dendritic cell vaccine and adoptive T cell therapy has triggered anti-tumor immune responses in patients with late-stage ovarian cancer. Four of six patients treated responded to the therapy, showing promising early results.
A preclinical study identifies Src, a master regulator of cancer cell proteins, as the key molecular switch affecting ovarian cancer progression. Beta blocker drugs mitigate this effect, reducing cancer deaths and mortality among patients with ovarian and cervical cancer.
A University of Central Florida professor has discovered a protein present in several types of cancer that could help prevent tumors from coming back. The protein, KLF8, appears to protect tumor cells from drugs and aid their regeneration.
Researchers develop SAPS algorithm to identify significant prognostic gene sets associated with patient survival, overcoming limitations of previous methods. The study found new prognostic signatures in breast and ovarian cancer subtypes, suggesting shared therapeutic targets and potential for improved diagnostics and treatments.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
Researchers created a genomic sequencing test, 'PapGene', using cervical fluid from routine Pap tests to detect ovarian and endometrial cancers with high accuracy. The test distinguished cancerous DNA from normal DNA, detecting both early and late-stage diseases.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
Researchers found that Xbp1s regulates liver metabolic switch after eating, while low iron accelerates H. pylori-induced gastric cancer. Additionally, p62 is crucial for brown fat thermogenesis, and dendritic cells play a protective role in atherosclerosis.
Among eligible women, 19.1% underwent risk-reducing salpingo-oophorectomy (RRSO) and 39.6% used screening procedures, with women receiving a positive BRCA test result having increased odds of these interventions, while true-negative results were associated with reduced odds.
A nationwide survey of obstetricians and gynecologists found that many doctors perform routine pelvic exams in low-risk women due to misconceptions about ovarian cancer screening. The study suggests that the exams may be performed for non-clinical reasons, such as reassurance or expectation, rather than medical necessity.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
A study published in Cancer Discovery reveals that microRNAs can modify gene expression, converting normal fibroblasts into cancer-associated fibroblasts that promote tumor growth. The researchers identified three microRNAs involved in this process and found that inhibiting these signals could disrupt the cancer's support system.
Researchers have discovered a novel mechanism by which normal stromal cells around ovarian cancer cells are converted into cancer-promoting cells. Altering microRNA expression in these cells enhances tumor growth and metastasis, providing new potential therapeutic targets.
A UNM Cancer Center researcher is investigating the link between mitochondrial DNA and ovarian cancer. She hopes to identify genetic markers that could lead to a screening test or therapy, potentially increasing survival rates.